The Role Of Progestogens In Threatened And Idiopathic Recurrent Miscarriage

This article was published in the following Dove Press journal:
International Journal of Women’s Health

Abstract: It is well known that progesterone plays a major role in the maintenance of pregnancy, particularly during the early stages, as it is responsible for preparing the endometrium for implantation and maintenance of the gestational sac. The management of pregnant women at risk of a threatened or idiopathic recurrent miscarriage is complex and critical. Therefore, a group of obstetricians and gynecologists practicing in Saudi Arabia gathered to update the 2014 Saudi guidelines for threatened and recurrent miscarriage management. In preparation, a literature review was conducted to explore the role of oral, vaginal, and injectable progestogens: this was used as a basis to develop position statements to guide and standardize practice across Saudi Arabia.

Keywords: idiopathic recurrent miscarriage, progesterone, progestin, progestogen, Saudi Arabia, threatened miscarriage

Introduction
It is estimated that about 70% of conceptions are lost prior to live birth: 30% due to implantation failure, 30% following implantation but before a missed period, and about 10% as clinical miscarriage. Despite considerable advances in science and technology, preventing and managing patients at risk of clinical miscarriage in early pregnancy continues to be a distressing problem. The possible causes of miscarriage, which can be broadly divided into two categories, are listed in Table 1.

The Role Of Hormones In Pregnancy
Pregnancy is a hormone-mediated physiological state that involves a decrease in uterine vascular tone and an increase in uterine blood flow. Progesterone and estrogen are two key hormones that remain elevated during pregnancy and play significant roles in causing anatomical adjustments within the uterus to create an environment conducive to fetal growth.

Progesterone, rightly called the “pregnancy hormone”, is crucial in the maintenance of pregnancy as it is involved in modulation of the maternal immune response, suppression of inflammatory response, reduction of uterine contractility, improvement of utero-placental circulation, and luteal-phase support. Particularly in early pregnancy, progesterone is responsible for preparing the endometrium for implantation and maintenance of the gestational sac in the uterus.

Mechanisms Involved In Miscarriage
Considerable progress has been made in the fields of cytogenetics and immunogenetics, which has in turn contributed to a better understanding of the mechanisms...
involved in miscarriage. The main mechanisms involved in early miscarriage include chromosomal abnormalities or aberrations, immunological and immunogenetic causes, thrombophilies, endocrinological disorders, sperm DNA fragmentation, failure of embryo selection, uterine malformations, hCG gene polymorphisms and epigenetic causes, and lifestyle factors. Fetal malformations were found to be responsible for 85% of early clinical miscarriages, with chromosomal abnormalities found in one partner of 3–6% of couples experiencing a recurrent miscarriage, which is ten times higher than the rate in the general population. Cytokine-mediated immunological reactions are estimated to be responsible for 40–60% of all cases of idiopathic recurrent spontaneous miscarriages.

In recent years, it has become increasingly clear that maternal immune tolerance of the fetus is key to promoting fetal survival. It has been suggested that successful pregnancy is associated with downregulation of Th1-type activity and enhancement of Th2-type activity. Studies have reported that women with spontaneous recurrent miscarriages have elevated levels of the Th1 cytokines interleukin (IL)-2 and interferon-γ and decreased levels of the Th2 cytokine IL-10, as assessed by antigen- and mitogen-induced activation of peripheral blood mononuclear cells. Progesterone favors the development of human T-cells producing Th2 cytokines and blocks the production of Th1 cytokines, indicative of its role in pregnancy maintenance.

### Terminology

At present, there is no consensus on the number of miscarriages needed to fulfill the criteria for recurrent miscarriage; however, this group of experts from Saudi Arabia agreed to follow the guidelines proposed by the European Society of Human Reproduction and Embryology (ESHRE), which define recurrent miscarriage as “the loss of two or more pregnancies.” A “biochemical loss” is defined as a miscarriage that occurs (usually before 6 weeks of gestation) following a positive urinary human chorionic gonadotropin (hCG) or a raised serum β-hCG, but prior to ultrasound or histological verification. The term clinical miscarriage is used when ultrasound examination or histological evidence has confirmed that an intrauterine pregnancy has existed. Clinical miscarriages may be subdivided into early (before gestational week 12) and late (gestational weeks 12 to 21).

As per the expert panel, patients with a biochemical and ultrasound confirmation of pregnancy depicting the clinical signs of threatened miscarriage should be thoroughly investigated prior to prescribing treatment.

### Materials And Methods

A group of nine obstetricians and/or gynecologists, each with over 10 years of clinical practice experience in Saudi Arabia, met on November 15, 2018, and January 31, 2019, in Jeddah, Saudi Arabia, with the objective of updating the current Saudi guidelines for threatened and recurrent miscarriage management, which were published in 2014. During the first meeting, the initial guidelines were reviewed, recent updates in clinical practice identified, and gaps in practice enumerated. Based on this evaluation, the expert panel took 2 months to conduct a literature review on the role of oral, vaginal, and injectable progestogens in early pregnancy and in the prevention and treatment of threatened and idiopathic recurrent miscarriage.

The experts also collated information on progestogens currently approved by the Saudi Food and Drug Administration (SFDA) for the treatment of threatened and idiopathic recurrent miscarriage. A literature review was conducted using PubMed. Articles were short-listed based on title and then abstracts were reviewed for relevance. Only articles published in English were reviewed. The expert panel presented all collated information during the second meeting and used it as a basis for the position statements presented within this paper.

This paper will outline recommendations for using progestogens in threatened and idiopathic recurrent miscarriage,
in Saudi Arabia. This document is intended as a reference for local general physicians, obstetricians/gynecologists, and fertility specialists for the management of the aforementioned patients. However, physicians are required to manage patients based on the best available evidence and using their clinical judgment and should also take factors such as patient characteristics, drug profile, and available resources into consideration.

**Review Summary**

**What Progestogens Are Currently Available For The Treatment Of Threatened And Idiopathic Recurrent Miscarriage?**

At present, the SFDA has registered only two of the four products listed in Table 2 for the treatment of threatened and idiopathic recurrent miscarriage, both are progestogens. It is important that hormonal treatment prescriptions are limited to those indicated for the treatment of threatened or recurrent miscarriage by the SFDA.

**What Is The Role Of Oral Progestogens In The Prevention And Treatment Of Threatened And Idiopathic Recurrent Miscarriage?**

**Oral Micronized Progesterone**

Available data suggest that oral micronized progesterone may have a role in preterm labor but not in threatened or recurrent miscarriage.

**Dydrogesterone (Oral Progestogen)**

**Threatened Miscarriage**

Based on data from recent systematic reviews and meta-analyses, oral dydrogesterone effectively prevents miscarriage in pregnant women experiencing threatened miscarriage. The meta-analysis by Carp et al, which collated data from five randomized trials including 660 patients, reported that the miscarriage rate was 13% in women on dydrogesterone versus 24% in the control group (odds ratio [OR] 0.47, 95% confidence interval [CI] 0.31–0.7, 11% absolute reduction in miscarriage rate). Carp et al concluded that the 47% reduction in the odds of miscarriage observed with dydrogesterone compared with standard of care was indicative of real treatment effect. A more recent study by Lee et al that collated data from nine randomized trials including 913 patients (322 on dydrogesterone, 213 vaginal progesterone, and 378 control) reported that the incidence of miscarriage was significantly lower in the oral dydrogesterone group than in the control group (11.7% vs 22.6%; OR 0.43; 95% CI 0.26–0.71; \( P = 0.001; I^2 = 0\%\)). Similar findings were reported by Wahabi et al: oral progestogens (dydrogesterone and micronized progesterone) were found to reduce the rate of miscarriage compared with no treatment (risk ratio [RR] 0.57; 95% CI 0.38–0.85; three trials; 408 patients). Wang et al pooled data from eight randomized controlled trials, including 845 women with threatened miscarriage, and reported that women receiving dydrogesterone were at a lower risk of miscarriage (RR 0.49, 95% CI 0.33–0.75) than women on natural progesterone (RR 0.69, 95% CI 0.40–1.19). Furthermore, women treated with oral progestogens demonstrated a lower risk of miscarriage (RR 0.55, 95% CI 0.38–0.79) than those on vaginal progesterone (RR 0.58, 95% CI 0.28–1.21).

Four recent clinical trials have reported beneficial effects with dydrogesterone in threatened miscarriage. In a study by El-Zibdeh and Yousef, 146 women presenting with mild-to-moderate vaginal bleeding during the first trimester were randomized to 10 mg oral dydrogesterone twice daily (\( n = 86 \)) or no treatment (\( n = 60 \)). The incidence of miscarriage was found to be 17.5% with dydrogesterone versus 25% with no treatment (\( P < 0.05 \)). Another open-label study reported that both dydrogesterone (\( n = 59 \)) and micronized progesterone (\( n = 59 \)) effectively reduced the extent of bleeding within 4–10 days, with comparable miscarriage rates. Furthermore, it was

<table>
<thead>
<tr>
<th>Generic Name</th>
<th>Trade Name</th>
<th>Unit Strength</th>
<th>Route Of Administration</th>
<th>Indicated For TM And RM</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hydroxyprogesterone caproate</td>
<td>Proluton Depot</td>
<td>250/500 mg/mL</td>
<td>Intramuscular injection</td>
<td>Yes</td>
</tr>
<tr>
<td>Dydrogesterone</td>
<td>Duphaston</td>
<td>10 mg</td>
<td>Oral tablet</td>
<td>Yes</td>
</tr>
<tr>
<td>Progesterone</td>
<td>Cyclogest</td>
<td>200/400 mg</td>
<td>Vaginal pessaries</td>
<td>No</td>
</tr>
<tr>
<td>Progesterone</td>
<td>Endometrin</td>
<td>100 mg</td>
<td>Vaginal tablet</td>
<td>No</td>
</tr>
</tbody>
</table>

**Table 2** Progestogens Currently Available For The Treatment Of Threatened (TM) And Idiopathic Recurrent Miscarriage (RM) In Saudi Arabia
found that patients with low progesterone (<35 nmol/L) were 23 times more likely to experience a miscarriage than women with high progesterone (≥35 nmol/L) (OR 23.8; 95% CI 6.5–86.6; \( P < 0.0001 \)). Overall both treatments were tolerated well, although drowsiness was experienced by a greater number of patients on micronized progesterone compared with dydrogesterone (\( P = 0.003 \)). Pandian reported that the rate of continuing pregnancy beyond 20 weeks was statistically higher with dydrogesterone (87.5%) versus conservative management (71.6%) (\( P < 0.05 \)). The rate of miscarriage was also lower with dydrogesterone versus control (12.5% vs 28.4%; \( P < 0.05 \)), with no differences in rates of cesarean section, placenta previa, antepartum hemorrhage, preterm labor, pregnancy-induced hypertension, or low birth weight (<2500 g) babies. In a similar study by Omar et al, the rate of continuing pregnancy beyond 20 weeks was significantly higher with dydrogesterone versus conservative treatment (95.9% vs 86.3%; OR 3.773; 95% CI 1.009–14.108; \( P = 0.037 \)). In terms of safety, no intrauterine deaths, congenital abnormalities, or pregnancy-related complications were reported with dydrogesterone.

### Idiopathic Recurrent Miscarriage

Data from two recent systematic reviews and meta-analyses showed that dydrogesterone could be effectively used to prevent miscarriage in women with a history of idiopathic recurrent miscarriage. Carp collated data from three studies, including 509 patients, and reported that the rate of miscarriage with dydrogesterone was lower than with control (10.5% vs 23.5%; OR 0.29; 95% CI 0.13–0.65; 13% absolute reduction in miscarriage). Sacone et al collated data from 10 trials, 1586 patients, and reported that women randomized to receive progestogens in the first trimester and before 16 weeks of gestation had a lower risk of recurrent miscarriage (RR 0.72, 95% CI 0.53–0.97) and higher rate of live birth (RR 1.07, 95% CI 1.02–1.15) versus control/placebo.

Looking at clinical trial data, Kumar et al reported that the risk of miscarriage after three miscarriages was 2.4 times higher with placebo than dydrogesterone (RR 2.4; 95% CI 1.3–5.9). Both mean gestational age at delivery and birth weight were higher with dydrogesterone compared with placebo. In another study, dydrogesterone was found to significantly reduce the rate of miscarriage versus no treatment (13% vs 29%; \( P = 0.028 \)) with no reports of pregnancy complications or congenital abnormalities when given to women with history of idiopathic recurrent miscarriages.

There are few reports of side effects in mothers taking dydrogesterone. Some studies have reported drowsiness, nausea and vomiting, although such symptoms might be associated with the pregnancy itself. Recommendations 1: Oral progestogens, namely dydrogesterone, are well tolerated and effectively reduce miscarriages in women at risk of threatened or idiopathic recurrent miscarriages.

### What Is The Role Of Vaginal Progestogens In The Prevention And Treatment Of Threatened And Idiopathic Recurrent Miscarriage?

Data on the efficacy and safety of vaginal progestogens are limited. A single-blind study by Yassaee et al that included 60 pregnant women with threatened miscarriage reported that progesterone suppositories (400 mg) reduced the number of miscarriages compared with control (6 vs 10 cases); however, this difference was not statistically significant. In a single-center, randomized, double-blind study including 50 women with a previous diagnosis of inadequate luteal phase and threatened miscarriage, vaginal progesterone gel (Crinone 8%) was found to help reduce pain and the frequency of uterine contractions within 5 days of administration (\( P < 0.005 \)), with a reduction in the rate of miscarriage after 60 days (\( P < 0.05 \)), compared with placebo. More recently, a large randomized trial found that micronized vaginal progesterone was no better than placebo for the treatment of threatened miscarriage. However, the authors cautioned that other formulations of progestational agents have different molecular structures and therefore potentially different mechanisms of actions and pharmacologic features.

The multicenter, randomized, double-blind, placebo-controlled PROMISE study exploring the effect of micronized vaginal progesterone (400 mg capsules) in women with a history of unexplained recurrent miscarriage (n = 836; 404 progesterone, 432 placebo) did not find any benefit of vaginal progesterone in improving rates of live birth, clinical pregnancy between 6 and 8 weeks of gestation, ongoing pregnancy at 12 weeks of gestation, miscarriage, ectopic pregnancy, stillbirth, neonatal survival, or neonatal congenital anomalies. In contrast, in a similar study, Ismail et al reported that vaginal progesterone (400 mg pessaries) significantly reduced the rate of miscarriage compared with placebo (12.4% vs 23.3%; \( P = 0.001 \)) in addition to an improvement in live birth rate (9.6 vs 10.5%).
77.4%) and continuation of pregnancy beyond 20 weeks (87.6 vs 76.7%), both of which were statistically significant ($P < 0.05$). However, a recent Cochrane review, which included data from the Ismail study, demonstrated no difference between the incidences of recurrent miscarriage in patients receiving placebo (n=763) and patients receiving vaginal progesterone (n = 738), with a RR of 0.73 (95% CI 0.40–1.31).

Guidelines published by ESHRE, European Progestin Club (EPC), the German Society of Gynecology and Obstetrics (DGGG), Austrian Society of Gynecology and Obstetrics (ÖGGG), and Swiss Society of Gynecology and Obstetrics (SGGG) confirm that vaginal progesterone has no beneficial effect in early pregnancy and does not improve live birth rates in women with unexplained recurrent miscarriage and therefore cannot be recommended for routine use in the treatment of threatened or recurrent miscarriage.

Recommendation 2: Available evidence is insufficient to recommend the use of vaginal progestogens (capsule, suppository, micronized, or gel) for the treatment of threatened or recurrent miscarriage.

**What Is The Role Of Injectable Progestogens In The Prevention And Treatment Of Threatened And Idiopathic Recurrent Miscarriage?**

Many studies refer to the benefit of intramuscular progestogens for luteal-phase support and for treating preterm birth, but not to prevent/treat threatened or recurrent miscarriage. Only one randomized controlled study, by Beigi et al, reported that the risk of preterm labor in pregnant women with threatened miscarriage at <34 weeks’ gestation was similar in intramuscular (8.6%) and vaginal (6.52%) progesterone groups [RR 1.31; 95% CI 0.47–3.66; $P = 0.59$].

Recommendation 3: There is insufficient evidence to support the use of injectable progestogens in miscarriage prevention and treatment.

**What Is The Role Of Combination Treatment (Oral And/Or Vaginal And/Or Injectable) In The Prevention And Treatment Of Threatened And Idiopathic Recurrent Miscarriage?**

There are no published articles assessing the efficacy and safety of progestogens in combination administered through different routes. Furthermore, the uterus is a hormone-sensitive organ that responds to the presence of estrogen and progesterone, each binding to their cognate receptors (ESR1 and PGR, respectively) and working in concert to establish and maintain pregnancy. Disruption to this balance may increase the likelihood of miscarriage by lowering the number of available progesterone receptors and/or estrogen receptors within the endometrium or by the dysregulation of gene transcription and uterine biology.

Recommendation 4: There is no evidence to support the use of combination progestogens in the prevention and treatment of threatened and idiopathic recurrent miscarriage. Progestogen monotherapy administered in the appropriate dose is recommended.

**Are The Available Progestogens Safe In Early Pregnancy?**

Clinical studies of oral and vaginal routes of administration are associated with acceptable and minimal side effects, with fatigue, fluid retention, lipid level alterations, dysphoria, hypercoagulant states, and increased androgenicity reported most commonly. Natural progestogens are reported to have milder side effects, with oral micronized natural progestogens having fewer side effects than natural progestones. However, given the poor bioavailability of oral micronized progesterone, high doses may be required, which may result in drowsiness and liver toxicity.

Dydrogesterone, a progestogen that is highly selective for the progesterone receptor, lacks estrogenic, androgenic, anabolic, and corticoid properties; most studies report no significant side effects including no masculinization of the female fetus or congenital abnormalities. In comparison with micronized progesterone, dydrogesterone was found to cause significantly fewer cases of drowsiness ($P = 0.003$), with no differences in nausea, vomiting, giddiness, bloating, diarrhea, or headache. Astoundingly, although 38 million women were treated with dydrogesterone between 1977 and 2005, with >10 million fetuses exposed in utero, only 28 cases of potential links between its use and congenital birth defects were reported. Thus, dydrogesterone is very unlikely to be teratogenic. Furthermore, dydrogesterone has been used for a variety of indications worldwide in an estimated 113 million women since 1960, with approximately 20 million fetuses being exposed in utero, which demonstrates its continued favorable safety and tolerability profile during pregnancy.
Intramuscular progestogen is commonly associated with injection-site reactions, including soreness, swelling, itching, and bruising, with daily injections associated with pain at injection site and local abscess formation. Carmichael et al reported that intake of progestogens during pregnancy was associated with an increased risk of hypospadias, with an OR of 3.7 (95% CI 2.3–6.0). Looking at data published before 1990, two studies report no congenital abnormalities with use of progestogens (vaginal and intramuscular) during pregnancy. In 2008, the Practice Committee of the American Society for Reproductive Medicine stated that there is no evidence to indicate that supplementation with progestogens during early pregnancy poses any significant risk of hypospadias or other types of birth defect. For treatment during pregnancy, progestogens with the least androgenic or with anti-androgenic properties are particularly sought because they are expected to cause the least alterations in the sexual development of a fetus.

Clinical studies in which a limited number of women were treated with dydrogesterone early in pregnancy have not shown any increase in the risk of hypospadias. The Cochrane Reviews on the role of progestogen treatment during pregnancy and the meta-analysis by Carp concluded that no safety issues were suspected when comparing newborns of mothers who had received progestogens with those who did not, including no increased risk of congenital abnormalities.

Recommendation 5: Progestogens are generally well tolerated, with minimal side effects. Although progestogen administration during the first trimester was linked to hypospadias risk, recent and more thorough reports have not shown an increase in the rate of hypospadias.

**Position Statements**

**Threatened Miscarriage**

1. For women presenting with a clinical diagnosis of threatened miscarriage, dydrogesterone may reduce the rate of miscarriage.
2. Oral dydrogesterone should be offered. Manufacturer dosage: 40 mg loading, then 30 mg once daily until symptoms (bleeding) remit. If symptoms persist/recur, increase dose by 10 mg three times a day. Maintain effective dose for 1 week after symptoms have ceased and then gradually reduce dose. Immediately resume treatment at effective dose, if symptoms recur.

**Recurrent Miscarriage**

1. Thorough investigations are warranted to rule out other causes of miscarriage. Once ruled out, a diagnosis of idiopathic recurrent miscarriage is confirmed.
2. For women presenting with a clinical diagnosis of idiopathic recurrent miscarriage (having experienced two or more), there is a reduction in the rate of miscarriage with the use of dydrogesterone.
3. Dydrogesterone should be administered as early as possible, at the diagnosis of pregnancy or during the luteal phase, in stimulated cycles.
4. Oral dydrogesterone should be offered. Manufacturer dosage: 10–20 mg daily, until the 20th week of pregnancy. Treatment should preferably start before conception. If symptoms of threatened miscarriage occur during treatment, continue treatment as stated for that indication.

**Acknowledgments**

The authors would like to thank Abbott for providing funding for medical writing assistance. Medical writing support in the development of this manuscript was provided by Leris D’Costa of OPEN Health Dubai, funded by Abbott, Saudi Arabia. Abbott played no role in the collection, analysis, and interpretation of data or in the preparation of this manuscript. The consensus meetings held on November 15, 2018, and January 31, 2019, in Jeddah, Saudi Arabia, were sponsored by Abbott, Saudi Arabia. Sponsorship included travel expenses and an honorarium for participating authors.

**Author Contributions**

Hisham Arab was involved in the conception and execution of the project and helped outline and draft the manuscript. All authors were involved in the acquisition and interpretation of the data, provided critical comments and concepts during the consensus meeting that were incorporated into the manuscript. All authors conducted literature reviews in support of the recommendations; participated in the consensus meeting for generating recommendations; and contributed to the development, drafting or revising, and finalization of the manuscript. All authors approved the final submitted version of the manuscript. All authors agree to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.
Disclosure
Hisham Arab has received speaker honoraria from Bayer, Abbott, and MSD, and advisor honoraria from Vifor and Sanofi. The authors report no other conflicts of interest in this work.

References